Cognis Group Blog
  • Home
  • Foresight
  • Strategic Partnering
  • Contact
Cognis Group Blog
  • Home
  • Foresight
  • Strategic Partnering
  • Contact
Strategic Partnering

Looking for a disruptive equipment mounting solution? Here is one to consider.

A standardized system can simplify, streamline, and ruggedize the mounting of tools, instrumentation, and other equipment in the healthcare setting.

October 29, 2020
Read more
Strategic Partnering

Scouting Opportunity for Modified Transdermal Patch Drug Delivery System for Diabetes, Parkinson’s, and Other Indications

Our client is currently developing a revolutionary new transdermal drug delivery system that leverages the benefits of ultrasound.

August 28, 2020
Read more
Strategic Partnering

Outlicensing Opportunity for Technology Platform for Co-Development and Licensing in Oncology and Vaccines

ur client is currently developing a new functionalized silica nanoparticle as a drug delivery vector for nucleic acid payloads.

August 28, 2020
Read more
Strategic Partnering

Scouting Opportunity for Pharmaceutical products marketed in Europe and specifically Germany within Anesthetics and Analgesic

Our client wishes to acquire injectable products that are currently marketed in Germany.

August 28, 2020
Read more
Strategic Partnering

Seeking Partner for Speech Analysis Technology Platform for use in HDMI pass-through devices, end user devices, content provider software

Our client has developed a digital signal processing algorithm and system that effectively removes undesired audio from television programming.

August 28, 2020
Read more
Strategic Partnering Uncategorized

Scouting for Specific Prescription Rx and Generics in Respiratory, Diabetes, Ophthalmology, Anti-coagulant, Hypertension, Antibiotic, Analgesics for the Saudi Arabian Markets

Our client is identifying pharmaceuticals for in-licensing, supply, and tech transfer with regional exclusivity in Saudi Arabia.

August 28, 2020
Read more
Strategic Partnering

Outlicensing opportunity for Proprietary Compound and Nasal Spray for the Treatment of Obesity

Both ABSOLVE and ABSCENT have been evaluated in the clinic and have been more effective / better tolerated than other obesity therapeutics.
Average weight loss is 10 lbs. during the first month’s use (observed range = 4 lbs. to 15 lbs.) and 2 lbs. to 10 lbs. per month thereafter.
ABSOLVE’s APIs are both components of other diet medicines.

August 28, 2020
Read more
Strategic Partnering Uncategorized

Seeking Investment for Osteoarthritis Disease Modification Pharmaceutical

First in class, disease-modifying, once a year infusion for osteoarthritis. Company seeking investment

August 28, 2020
Read more
Strategic Partnering

Scouting Opportunity for Prescription, Orphan, Specialty for Switzerland

Our client is a pharmaceutical company seeking US FDA and/or EMA approved Prescription (Rx) Drugs and Medical Foods for the Swiss market in Oncology, Hematology, Infectious Disease, Hepatology, Gastrology, Transplant, Hematology, and Hepatology.

August 28, 2020
Read more
Strategic Partnering

Outlicensing Opportunity for Implantable Testosterone Pellets for Regions Outside of the UK

Our client has developed a subcutaneous testosterone implant system that overcomes disadvantages with competing HRT products.

August 28, 2020
Read more
Newer postsOlder posts

2020 Cognis Group. All Rights Reserved.